These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 26797400)

  • 1. Thymic Activity and T Cell Repertoire Recovery after Autologous Hematopoietic Stem Cell Transplantation Preceded by Myeloablative Radiotherapy or Chemotherapy.
    Głowala-Kosińska M; Chwieduk A; Smagur A; Fidyk W; Najda J; Mitrus I; Giebel S
    Biol Blood Marrow Transplant; 2016 May; 22(5):834-42. PubMed ID: 26797400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Liu HW; Seftel MD; Rubinger M; Szwajcer D; Demers A; Nugent Z; Schroeder G; Butler JB; Cooke A
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):513-20. PubMed ID: 20137862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age.
    Castermans E; Hannon M; Dutrieux J; Humblet-Baron S; Seidel L; Cheynier R; Willems E; Gothot A; Vanbellinghen JF; Geenen V; Sandmaier BM; Storb R; Beguin Y; Baron F
    Haematologica; 2011 Feb; 96(2):298-306. PubMed ID: 20934996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
    Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
    Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
    Brice P; Marolleau JP; Dombret H; Lepage E; Baruchel A; Adam M; Miclea JM; Sitthy X; Gisselbrecht C
    Bone Marrow Transplant; 1992 May; 9(5):337-42. PubMed ID: 1352162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
    William BM; Loberiza FR; Whalen V; Bierman PJ; Bociek RG; Vose JM; Armitage JO
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):417-23. PubMed ID: 23773453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-transplantation thymic function is associated with the risk of acute graft versus host disease and cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation.
    Yang X; Sun Y; Zhang S; Yang H; Wei J; He Y; Yang D; Jiang E; Han M; Qin X; Feng S
    Hematology; 2018 Jan; 23(1):30-37. PubMed ID: 28532344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma.
    Ron-Magaña AL; Fernandez-Vargas OE; Barrera-Chairez E; Ron-Guerrero CS; Bañuelos-Ávila AJ
    Ann Transplant; 2019 Oct; 24():584-587. PubMed ID: 31636248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
    Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
    J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4
    Batorov EV; Tikhonova MA; Kryuchkova IV; Sergeevicheva VV; Sizikova SA; Ushakova GY; Batorova DS; Gilevich AV; Ostanin AA; Shevela EY; Chernykh ER
    Int J Hematol; 2017 Jul; 106(1):108-115. PubMed ID: 28293817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
    Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
    Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
    Chen YB; Lane AA; Logan B; Zhu X; Akpek G; Aljurf M; Artz A; Bredeson CN; Cooke KR; Ho VT; Lazarus HM; Olsson R; Saber W; McCarthy P; Pasquini MC
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1046-1053. PubMed ID: 25687795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning.
    Loh SM; Ratnagopal P; Tan HC; Goh YT; Koh BC; Koh LP; Linn YC; Hwang WY
    Int J Hematol; 2006 May; 83(4):368-9. PubMed ID: 16757442
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution.
    Douek DC; Vescio RA; Betts MR; Brenchley JM; Hill BJ; Zhang L; Berenson JR; Collins RH; Koup RA
    Lancet; 2000 May; 355(9218):1875-81. PubMed ID: 10866444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
    Fu H; Xu L; Liu D; Liu K; Zhang X; Chen H; Chen Y; Han W; Wang Y; Wang J; Wang F; Huang X
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1176-82. PubMed ID: 24747336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymopoiesis in Pre- and Post-Hematopoietic Stem Cell Transplantation.
    da Rocha LKA; Freschi de Barros S; Bandeira F; Bollini A; Testa LHA; Simione AJ; Souza MOE; Zanetti LP; de Oliveira LCS; Dos Santos ACF; de Souza MP; Colturado VAR; Kalil J; Machado CM; Guilherme L
    Front Immunol; 2018; 9():1889. PubMed ID: 30245685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
    Truelove E; Fox C; Robinson S; Pearce R; Perry J; Kirkland K; McQuaker G; Pagliuca A; Johnson P; Russell N; Cook G;
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):483-8. PubMed ID: 25490180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
    Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recovery of mucosal-associated invariant T cells after myeloablative chemotherapy and autologous peripheral blood stem cell transplantation.
    Novak J; Dobrovolny J; Brozova J; Novakova L; Kozak T
    Clin Exp Med; 2016 Nov; 16(4):529-537. PubMed ID: 26409838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
    O'Meara A; Halter J; Heim D; Gerull S; Bucher C; Passweg J; Buser A; Stern M
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):82-6. PubMed ID: 22897965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.